Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
Research Watch

Loss of DNA Repair Drives Neoantigen Renewal and Inhibits Tumor Growth

DOI: 10.1158/2159-8290.CD-RW2017-228 Published January 2018
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: DNA mismatch repair in tumors promotes enhanced immune surveillance.

  • Concept: Loss of DNA mismatch repair drives hypermutation to increase the tumor neoantigen repertoire.

  • Impact: Inhibition of DNA repair processes is a potential adjuvant approach for immunotherapy.

Mutations in genes associated with DNA mismatch repair (MMR), such as MLH1, result in a microsatellite instability (MSI) phenotype and promote tumor initiation and growth; however, MMR-deficient cancers are associated with favorable prognosis. It has recently been shown that immune checkpoint blockade is more efficacious in patients with MSI tumors than in patients with microsatellite stable (MSS) tumors. To elucidate the role of MMR in tumorigenesis and immunotherapy response, Germano and colleagues performed CRISPR/Cas9-mediated targeting of Mlh1 in murine breast, colon cancer, and pancreatic ductal adenocarcinoma cells to generate isogenic sets of MMR-proficient and MMR-deficient cell lines. While both MMR-proficient and MMR-deficient cells grew at similar rates and rapidly formed tumors in immunocompromised mice, only MMR-proficient cells formed subcutaneous and orthotopic tumors in immune-competent syngeneic mice; however, transplantation of MMR-deficient tumors grown in immunocompromised mice to immune-competent mice resulted in tumor growth. Treatment with combined anti–PD-1 and anti-CTLA4 antibodies resulted in decreased growth of transplanted MMR-deficient tumors, but not MMR-proficient tumors, in immune-competent mice. Consistent with these findings, MMR-deficient cells formed tumors in immune-competent mice depleted of CD8+ T cells. Longitudinal exome sequencing revealed that mutational load, the number of neoantigens, and T-cell receptor diversity increased over time in MMR-deficient, but not MMR-proficient, cells. Further, treatment with the genotoxic agent temozolomide inactivated MMR in MMR-proficient cancer cells, resulting in increases in mutational load and neoantigens and enhanced tumor immune surveillance in vivo. Similarly, decreased expression of the DNA repair enzyme MGMT in human cancer cells and tumors treated with temozolomide was associated with alterations in MMR genes and high tumor mutation burden and number of neoantigens. These findings show that MMR deficiency induces neoantigen production to promote durable immune surveillance and suggest that inactivation of DNA repair may enhance the immunogenicity of MSS tumors.

Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 2017;552:116–20.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2018 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 8 (1)
January 2018
Volume 8, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Loss of DNA Repair Drives Neoantigen Renewal and Inhibits Tumor Growth
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Loss of DNA Repair Drives Neoantigen Renewal and Inhibits Tumor Growth
Cancer Discov January 1 2018 (8) (1) 11; DOI: 10.1158/2159-8290.CD-RW2017-228

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Loss of DNA Repair Drives Neoantigen Renewal and Inhibits Tumor Growth
Cancer Discov January 1 2018 (8) (1) 11; DOI: 10.1158/2159-8290.CD-RW2017-228
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation
  • R-Loops May Drive Embryonal Tumors with Multilayered Rosettes
  • DDR-Defective Metastatic Prostate Cancers Are Susceptible to Olaparib
Show more Research Watch

DNA Repair

  • Release of Paused Pol II Induces Double-Strand Breaks in Normal Cells
  • UBQLN4 Regulates DNA Repair Pathway Choice
  • Nuclear cGAS Blocks DNA Repair to Drive Tumorigenesis
Show more DNA Repair
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement